Nevertheless, the quantitative systemic exposure to CNS‐derived proteins (e.g., Aβ, tau) after dcLVA and any long‐term hepatic/renal or hematological consequences remain unknown: to our knowledge, no published study in dcLVA for AD has prospectively and longitudinally monitored comprehensive liver function, kidney function, complete blood count, or inflammatory markers to address this concern.27, 51, 52. This evidence concerns the gene MAPT and Alzheimer disease.